title: Effects of long-term administration of a superactive agonistic and an antagonistic GnRH analog on the pituitary-gonad system.
abstract: A powerful GnRH antagonist: [Ac-D-Trp1,3,D-Cpa2,D-Lys6,D-Ala10]-GnRH (MI-1544) and a superactive GnRH agonist: [D-Phe6,desGly10]-GnRH(1-9)EA (OVURELIN) were used in long-term administration to compare their effects on the inhibition of ovulation, LH and progesterone (P) release, LH content of pituitaries as well as on the recovery period. Both analogs showed 100% inhibitory effects on ovulation in very low doses during the daily treatment for 21 days. The antagonist prevented LH release already after the first injection, decreased the serum P level to 40%, and increased the LH content of the pituitary up to 180%, inhibiting only the release but not the synthesis of LH. The agonist showed marked LH-releasing effects on the first day of the treatment, which were reduced to 12% on the 7th day. Serum P concentration was dropped to 68% by the end of the treatment. No change was found in the LH content of pituitaries in the group treated with the agonist. Ovaries showed polifollicular pictures in the antagonist-treated group, and persistent corpora lutea were seen in the ovaries from the agonist-treated group. Regular estrous cycles returned 13-15 days after ceasing the treatment with the antagonist and 3-5 days after ceasing the treatment with the agonist. No edema-inducing effect was observed after the injections of the antagonist in doses of 100 times higher than the single antiovulatory dose.
authors.affiliation: Department of Anatomy, University Medical School, Pécs, Hungary.
authors.forename: M
authors.initials: M
authors.lastname: Kovács
authors.forename: I
authors.initials: I
authors.lastname: Mezö
authors.forename: J
authors.initials: J
authors.lastname: Seprödi
authors.forename: V
authors.initials: V
authors.lastname: Csernus
authors.forename: I
authors.initials: I
authors.lastname: Teplán
authors.forename: B
authors.initials: B
authors.lastname: Flerkó
mesh_terms: D000818:Animals; D004487:Edema / Q000139:chemically induced; D004971:Estrus / Q000187:drug effects; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000494:pharmacology; D007150:Immunohistochemistry; D007986:Luteinizing Hormone / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D010053:Ovary / Q000187:drug effects*; D010060:Ovulation / Q000187:drug effects; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D010902:Pituitary Gland / Q000187:drug effects* / Q000378:metabolism; D011374:Progesterone / Q000378:metabolism; D011863:Radioimmunoassay; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors
chemical_list: D010446:Peptide Fragments; C062312:ovurelin; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; C040278:MI 1544; D007986:Luteinizing Hormone